A Case Report on Rituximab-induced Interstitial Lung Disease

Rituximab is a monoclonal antibody commonly used to treat various autoimmune diseases.However, its use has been associated with the development of interstitial lung disease (ILD), a severe and potentially fatal condition characterized by inflammation and fibrosis of the lungs.This case report describes the case of a patient who developed ILD following treatment with rituximab for Diffuse large B cell lymphoma.The patient presented with symptoms of shortness of breath, dry cough, and fever, and was diagnosed with ILD following a comprehensive evaluation.The patient was treated with corticosteroids and other immunosuppressive medications, with a favorable response.This report highlights the importance of recognizing and managing rituximabinduced ILD and underscores the need for close monitoring of patients receiving this drug.